CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
Continous IV infusion of Nesiritide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03234751
NCT03234751Phase 1Completed
CompareCT.gov

Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects

AdventHealth Translational Research Institute·interventional·Posted Jul 31, 2017·Updated Mar 10, 2020

In Brief

A Phase 1 clinical trial evaluating Continous IV infusion of Nesiritide, Hyperinsulinemic euglycemic clamp, and 1 other intervention for Diabetes. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of the study is to compare the effects of nesiritide to placebo administered by a continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy, obese, insulin resistant individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 31, 2017
Enrollment StartJul 13, 2017
Primary CompletionSep 24, 2018
Study CompletionFeb 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.9 years ago

Interventions

Continous IV infusion of Nesiritidedrug

Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.

Hyperinsulinemic euglycemic clampdrug

48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.

Placebodrug

48 hours of placebo.